Riverchase Wealth Management LLC Buys New Position in AbbVie Inc. $ABBV

Key Points

• Riverchase Wealth Management acquired 4,919 AbbVie shares worth approximately $1.24 million, making ABBV its 14th-largest holding. Institutional investors collectively own 70.23% of the company.
• AbbVie exceeded second-quarter expectations with $3.65 in EPS and $16.99 billion in revenue, representing 10.2% year-over-year growth. The company issued third-quarter EPS guidance of $3.84–$3.88.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $274.33, while AbbVie pays a quarterly dividend of $1.73 per share. Key positives include strong immunology sales and progress for UBRELVY and BOTOX, though the Apogee acquisition adds about $8 billion in debt.

Riverchase Wealth Management LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,919 shares of the company's stock, valued at approximately $1,238,000. AbbVie comprises 0.6% of Riverchase Wealth Management LLC's holdings, making the stock its 14th largest position.

Several other institutional investors and hedge funds have also modified their holdings of ABBV. Willner & Heller LLC raised its holdings in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after purchasing an additional 43 shares during the period. Bank of Jackson Hole Trust grew its holdings in shares of AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock worth $1,648,000 after purchasing an additional 44 shares during the period. Eclectic Associates Inc. ADV increased its position in AbbVie by 0.8% during the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company's stock worth $1,337,000 after purchasing an additional 45 shares in the last quarter. Imprint Wealth LLC increased its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Finally, Dogwood Wealth Management LLC raised its holdings in AbbVie by 10.8% in the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company's stock valued at $108,000 after buying an additional 46 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Price Performance

ABBV opened at $249.12 on Thursday. The stock has a market capitalization of $440.14 billion, a PE ratio of 70.37, a P/E/G ratio of 0.83 and a beta of 0.30. The firm's fifty day moving average price is $243.99 and its 200 day moving average price is $225.73. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the business posted $2.97 EPS. AbbVie's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie's payout ratio is currently 195.48%.

Analyst Ratings Changes

A number of research analysts have weighed in on ABBV shares. Royal Bank Of Canada lifted their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, July 10th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a research report on Tuesday, June 23rd. DZ Bank upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a report on Thursday, April 30th. HSBC reissued a "buy" rating and issued a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Finally, BMO Capital Markets boosted their price objective on AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and an average target price of $274.33.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canada supports UBRELVY reimbursement: Canada’s Drug Agency recommended reimbursement of UBRELVY for acute migraine treatment in adults. The decision could improve access and provide another growth opportunity for AbbVie’s neuroscience portfolio. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Positive Sentiment: BOTOX regulatory progress: AbbVie’s BOTOX filing helped attract investor attention, adding potential support for the aesthetics business and contributing to the stock’s recent strength. AbbVie Gains on Botox Filing
• Positive Sentiment: Immunology remains the key growth engine: Skyrizi and Rinvoq delivered strong sales, market-share gains and contributions from new indications, helping drive AbbVie’s second-quarter growth. Recent results also exceeded consensus estimates for earnings and revenue. How Much Did Immunology Drugs Contribute to AbbVie’s Q2 Performance?
• Neutral Sentiment: Pipeline updates provide optionality but limited immediate impact: AbbVie completed early testing of a venetoclax combination in high-risk myelodysplastic syndromes and completed a Phase 3 BOTOX jawline study. The updates advance development, but the reports did not provide definitive clinical results. AbbVie’s Venetoclax Combo in High-Risk MDS
• Neutral Sentiment: Analyst target increase reflects limited near-term upside: BNP Paribas Exane raised its price target from $218 to $247 while retaining a neutral rating, implying the shares were slightly above its revised valuation. Erste Group also modestly reduced its FY2027 EPS forecast but kept a Buy rating. BNP Paribas Exane AbbVie Price Target
• Negative Sentiment: Apogee acquisition increases leverage: Shareholders approved AbbVie’s Apogee Therapeutics acquisition, expanding the pipeline but requiring roughly $8 billion of additional debt. Investors focused on dividend safety may view the higher leverage and execution risk negatively. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source